Syfovre, also known as pegcetacoplan, is a medicine used to treat geographic atrophy, which is the advanced form of dry age-related macular degeneration. Geographic atrophy can cause irreversible ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Apellis is exclusively distributing injection kits with ...
A Media Snippet accompanying this announcement is available by clicking on the image or link below: WALTHAM, Mass., July 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today ...
Syfovre (pegcetacoplan) is given as an eye injection by your doctor, typically once every 25 to 60 days. Syfovre belongs to a group of drugs called complement inhibitors. Its active ingredient is ...
SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpoint Data presented at the Clinical Trials at the Summit Meeting In a prespecified ...
Credit: Apellis. Syfovre is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration. Apellis announced that as part of its investigation into real-world safety ...
More than 100,000 vials have been distributed/administered between real world and clinical trials; since last update, confirmed one additional event of retinal ...
A Media Snippet accompanying this announcement is available by clicking on this link. WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results